Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma

Kyeongsoon Park, Gee Young Lee, Rang Woon Park, In-San Kim, Sang Yoon Kim, Youngro Byun

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose. Our previous study confirmed that heparin-deoxycholic acid conjugate (HD) had a potent antiangiogenic effect and safety to use for long-term treatment. Herein, the combined therapeutic effect of HD and doxorubicin (DOX) was evaluated against squamous cell carcinoma (SCC7) and B16F10 melanoma. Methods. The inhibitory effect of cell proliferation and cellular uptake of HD was studied in SCC7 and B16F10. The combination effects of HD and DOX were evaluated by measuring cytotoxicity and apoptosis as well as tumor growth and apoptosis in vivo against SCC7 and B16F10 tumor-bearing mice. Results. HD displayed potent inhibitory effect on SCC7 and B16F10 cell proliferation, but it showed a low cytotoxic effect. Concurrent treatment of HD and DOX displayed enhanced cytotoxic effects and apoptosis on SCC7 and B16F10. The cellular uptake of HD and DOX was affected by the collective cytotoxic effects of these two drugs: each drug suppressed the tumor growth, and their combined treatment enhanced apoptosis and collectively inhibited the tumor growth of SCC7 and B16F10 in vivo. Conclusion. These results demonstrated that HD with cytostatic and antiangiogenetic activities, enhanced the antitumor activity of DOX against SCC7 and B16F10, and the combined treatment of these two drugs might have enhanced therapeutic efficacy.

Original languageEnglish
Pages (from-to)268-276
Number of pages9
JournalPharmaceutical research
Volume25
Issue number2
DOIs
Publication statusPublished - 2008 Feb 1
Externally publishedYes

Fingerprint

Deoxycholic Acid
Doxorubicin
Heparin
Squamous Cell Carcinoma
Melanoma
Tumors
Apoptosis
Cell proliferation
Neoplasms
Bearings (structural)
Growth
Cell Proliferation
Pharmaceutical Preparations
Therapeutics
Cytostatic Agents
Therapeutic Uses
Cytotoxicity
Epithelial Cells
Safety

Keywords

  • Apoptosis
  • B16F10
  • Doxorubicin
  • Heparin-deoxycholic acid conjugate
  • SCC

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry
  • Pharmacology (medical)

Cite this

Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma. / Park, Kyeongsoon; Lee, Gee Young; Park, Rang Woon; Kim, In-San; Kim, Sang Yoon; Byun, Youngro.

In: Pharmaceutical research, Vol. 25, No. 2, 01.02.2008, p. 268-276.

Research output: Contribution to journalArticle

Park, Kyeongsoon ; Lee, Gee Young ; Park, Rang Woon ; Kim, In-San ; Kim, Sang Yoon ; Byun, Youngro. / Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma. In: Pharmaceutical research. 2008 ; Vol. 25, No. 2. pp. 268-276.
@article{c621f2fdcd65424f806933b96983761d,
title = "Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma",
abstract = "Purpose. Our previous study confirmed that heparin-deoxycholic acid conjugate (HD) had a potent antiangiogenic effect and safety to use for long-term treatment. Herein, the combined therapeutic effect of HD and doxorubicin (DOX) was evaluated against squamous cell carcinoma (SCC7) and B16F10 melanoma. Methods. The inhibitory effect of cell proliferation and cellular uptake of HD was studied in SCC7 and B16F10. The combination effects of HD and DOX were evaluated by measuring cytotoxicity and apoptosis as well as tumor growth and apoptosis in vivo against SCC7 and B16F10 tumor-bearing mice. Results. HD displayed potent inhibitory effect on SCC7 and B16F10 cell proliferation, but it showed a low cytotoxic effect. Concurrent treatment of HD and DOX displayed enhanced cytotoxic effects and apoptosis on SCC7 and B16F10. The cellular uptake of HD and DOX was affected by the collective cytotoxic effects of these two drugs: each drug suppressed the tumor growth, and their combined treatment enhanced apoptosis and collectively inhibited the tumor growth of SCC7 and B16F10 in vivo. Conclusion. These results demonstrated that HD with cytostatic and antiangiogenetic activities, enhanced the antitumor activity of DOX against SCC7 and B16F10, and the combined treatment of these two drugs might have enhanced therapeutic efficacy.",
keywords = "Apoptosis, B16F10, Doxorubicin, Heparin-deoxycholic acid conjugate, SCC",
author = "Kyeongsoon Park and Lee, {Gee Young} and Park, {Rang Woon} and In-San Kim and Kim, {Sang Yoon} and Youngro Byun",
year = "2008",
month = "2",
day = "1",
doi = "10.1007/s11095-007-9366-5",
language = "English",
volume = "25",
pages = "268--276",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma

AU - Park, Kyeongsoon

AU - Lee, Gee Young

AU - Park, Rang Woon

AU - Kim, In-San

AU - Kim, Sang Yoon

AU - Byun, Youngro

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Purpose. Our previous study confirmed that heparin-deoxycholic acid conjugate (HD) had a potent antiangiogenic effect and safety to use for long-term treatment. Herein, the combined therapeutic effect of HD and doxorubicin (DOX) was evaluated against squamous cell carcinoma (SCC7) and B16F10 melanoma. Methods. The inhibitory effect of cell proliferation and cellular uptake of HD was studied in SCC7 and B16F10. The combination effects of HD and DOX were evaluated by measuring cytotoxicity and apoptosis as well as tumor growth and apoptosis in vivo against SCC7 and B16F10 tumor-bearing mice. Results. HD displayed potent inhibitory effect on SCC7 and B16F10 cell proliferation, but it showed a low cytotoxic effect. Concurrent treatment of HD and DOX displayed enhanced cytotoxic effects and apoptosis on SCC7 and B16F10. The cellular uptake of HD and DOX was affected by the collective cytotoxic effects of these two drugs: each drug suppressed the tumor growth, and their combined treatment enhanced apoptosis and collectively inhibited the tumor growth of SCC7 and B16F10 in vivo. Conclusion. These results demonstrated that HD with cytostatic and antiangiogenetic activities, enhanced the antitumor activity of DOX against SCC7 and B16F10, and the combined treatment of these two drugs might have enhanced therapeutic efficacy.

AB - Purpose. Our previous study confirmed that heparin-deoxycholic acid conjugate (HD) had a potent antiangiogenic effect and safety to use for long-term treatment. Herein, the combined therapeutic effect of HD and doxorubicin (DOX) was evaluated against squamous cell carcinoma (SCC7) and B16F10 melanoma. Methods. The inhibitory effect of cell proliferation and cellular uptake of HD was studied in SCC7 and B16F10. The combination effects of HD and DOX were evaluated by measuring cytotoxicity and apoptosis as well as tumor growth and apoptosis in vivo against SCC7 and B16F10 tumor-bearing mice. Results. HD displayed potent inhibitory effect on SCC7 and B16F10 cell proliferation, but it showed a low cytotoxic effect. Concurrent treatment of HD and DOX displayed enhanced cytotoxic effects and apoptosis on SCC7 and B16F10. The cellular uptake of HD and DOX was affected by the collective cytotoxic effects of these two drugs: each drug suppressed the tumor growth, and their combined treatment enhanced apoptosis and collectively inhibited the tumor growth of SCC7 and B16F10 in vivo. Conclusion. These results demonstrated that HD with cytostatic and antiangiogenetic activities, enhanced the antitumor activity of DOX against SCC7 and B16F10, and the combined treatment of these two drugs might have enhanced therapeutic efficacy.

KW - Apoptosis

KW - B16F10

KW - Doxorubicin

KW - Heparin-deoxycholic acid conjugate

KW - SCC

UR - http://www.scopus.com/inward/record.url?scp=39149094951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149094951&partnerID=8YFLogxK

U2 - 10.1007/s11095-007-9366-5

DO - 10.1007/s11095-007-9366-5

M3 - Article

C2 - 17619999

AN - SCOPUS:39149094951

VL - 25

SP - 268

EP - 276

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 2

ER -